USRE50075E1 - Glucose level control system with offline control based on preceding periods of online control - Google Patents
Glucose level control system with offline control based on preceding periods of online control Download PDFInfo
- Publication number
- USRE50075E1 USRE50075E1 US17/313,401 US202117313401A USRE50075E US RE50075 E1 USRE50075 E1 US RE50075E1 US 202117313401 A US202117313401 A US 202117313401A US RE50075 E USRE50075 E US RE50075E
- Authority
- US
- United States
- Prior art keywords
- insulin
- dose
- correction
- glucose
- controller
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 214
- 239000008103 glucose Substances 0.000 title claims abstract description 214
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 286
- 102000004877 Insulin Human genes 0.000 claims abstract description 143
- 108090001061 Insulin Proteins 0.000 claims abstract description 143
- 229940125396 insulin Drugs 0.000 claims abstract description 143
- 238000012937 correction Methods 0.000 claims abstract description 142
- 235000012054 meals Nutrition 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 66
- 238000005259 measurement Methods 0.000 claims abstract description 58
- 230000004044 response Effects 0.000 claims abstract description 55
- 238000004422 calculation algorithm Methods 0.000 claims description 90
- 230000001517 counterregulatory effect Effects 0.000 claims description 45
- 238000005070 sampling Methods 0.000 claims description 45
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 230000000737 periodic effect Effects 0.000 claims description 15
- 230000000291 postprandial effect Effects 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 6
- 238000004590 computer program Methods 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 230000001550 time effect Effects 0.000 claims 4
- 230000001276 controlling effect Effects 0.000 claims 3
- 102000051325 Glucagon Human genes 0.000 abstract description 21
- 108060003199 Glucagon Proteins 0.000 abstract description 21
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract description 21
- 229960004666 glucagon Drugs 0.000 abstract description 21
- 238000004088 simulation Methods 0.000 description 21
- 238000004364 calculation method Methods 0.000 description 7
- 230000009471 action Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 235000021152 breakfast Nutrition 0.000 description 5
- 230000003345 hyperglycaemic effect Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000006362 insulin response pathway Effects 0.000 description 3
- 230000002608 insulinlike Effects 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16804—Flow controllers
- A61M5/16827—Flow controllers controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14288—Infusion or injection simulation
- A61M2005/14296—Pharmacokinetic models
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0486—Glucose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/005—Parameter used as control input for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Definitions
- Standard-of-care insulin therapies for regulating blood glucose in diabetes typically involve either multiple daily subcutaneous injections or subcutaneous infusion with an insulin pump.
- combinations of basal and bolus insulin are administered to meet the subject's basal metabolic insulin requirement; correction bolus doses are administered to regulate hyperglycemia; and additional meal bolus doses are added to provide insulin for food consumption.
- a correction bolus of insulin that is typically administered to treat a hyperglycemic state is based on an estimate of the individual's so-called “correction factor(s)”, which relate how much insulin is estimated by the user to adequately compensate for different levels of hyperglycemia.
- Correction factors are heuristically estimated on an individual basis and are modified (essentially by trial-and-error) from time to time. This is similar to how basal rates of insulin are heuristically estimated on an individual basis to provide basal metabolic insulin requirements.
- meal bolus insulin doses taken around food consumption are also typically estimated heuristically on an individual basis based on the quantity and content (carbohydrate and other) of the food, in conjunction with a heuristic estimate of the individual's so-called “insulin-to-carbohydrate ratio(s)”, among other factors such as the time of the day, physical activity, health state, emotional state, etc.
- the right correction bolus doses, insulin basal rates, and meal bolus doses alike are all essentially determined by trial-and-error experience and could vary significantly among individuals as well as for an individual over time; yet, they are all critical determinants of how well an individual is able to control their blood glucose.
- Dosing requirements are also subject to factors such as the time of the day, physical activity, health state, emotional state, etc., and could vary over periods of hours, days, or weeks due to transient changes (e.g. due to circadian hormonal fluctuations, current illness, physical activity, or emotional state) and/or periods of months or years due to developmental changes (e.g. due to hormonal changes that occur during puberty or menopause).
- the methods adapt to an individual user and do not require inputs such as “correction factors” and “insulin-to-carbohydrate” factors.
- a first disclosed method includes periods of online operation when a controller is operating to control the delivery of correction boluses of insulin automatically in response to regular glucose levels provided by a sensor at regular intervals (e.g., on the order of 1-15 minutes apart), also referred to as “sampling intervals”.
- Online operation of the controller refers to sampling intervals when there are a glucose measurements provided by the sensor and offline operation refers to sampling intervals when there are no glucose measurements provided by the sensor.
- the method further includes offline operation when a controller responds automatically to isolated glucose measurements (e.g., provided by the subject to the controller), using information that was gathered autonomously by the control system during preceding periods of online operation.
- a second disclosed method includes automatically calculating and administering meal bolus doses in response to meal announcements during periods of offline operation based on information that was gathered autonomously by the control system during preceding periods of online operation.
- the two methods involve autonomously generating relevant control parameters that are tailored to the individual and are continually converged upon and potentially modulated during periods of online operation.
- the control parameters are then employed in real time during periods of offline operation in order to regulate glucose levels without the need for the user to provide corresponding control parameters (e.g. insulin-to-carbohydrate ratios, or insulin correction factors).
- the methods may be used independently or together, and they may also be supplemented by analogous control methods for delivery of a counter-regulatory agent during offline operation, as described more below.
- FIG. 1 is a block diagram of a glucose control system
- FIG. 2 is a block diagram of a controller
- FIG. 3 is a flow diagram of a first method of operation of the system
- FIG. 4 is a graph depicting results of simulation of operation as a baseline for comparison with other simulations
- FIGS. 5 - 8 are graphs depicting results of simulations of operation according to the method of FIG. 3 ;
- FIG. 9 is a flow diagram of a second method of operation of the system.
- FIG. 10 is a graph depicting results of a simulation of operation according to the method of FIG. 9 ;
- FIG. 11 is a graph depicting results of simulation of operation according to both the methods of FIG. 3 and FIG. 9 ;
- FIG. 12 is a graph depicting results of simulation of operation incorporating use of a counter-regulatory agent.
- FIG. 1 illustrates an automated control system 10 for regulating the glucose level of an animal subject (subject) 12 , which may be a human.
- the subject 12 receives doses of insulin from one or more delivery devices 14 , for example infusion pump(s) coupled by catheter(s) to a subcutaneous space of the subject 12 .
- the delivery devices 14 may also deliver a counter-regulatory agent such as glucagon for control of glucose level under certain circumstances.
- the delivery devices 14 are preferably mechanically driven infusion mechanisms having dual cartridges for insulin and glucagon respectively.
- glucagon specifically, but it is to be understood that this is for convenience only and that other counter-regulatory agents may be used.
- the term “insulin” herein is to be understood as encompassing all forms of insulin-like substances including natural human or animal insulin as well as synthetic insulin in any of a variety of forms (commonly referred to as “insulin analogs”).
- a glucose sensor 16 is operatively coupled to the subject 12 to continually sample a glucose level of the subject 12 . Sensing may be accomplished in a variety of ways, generally involving some form of physical coupling 21 between the subject 12 and the glucose sensor 16 .
- a controller 18 controls operation of the delivery device(s) 14 as a function of a glucose level signal 19 from the glucose sensor 16 and subject to programmed input parameters (PARAMS) 20 which may be provided by a user such as the subject 12 .
- PARAMS programmed input parameters
- One input parameter for automatic operation is the weight of the subject 12 .
- One feature of the disclosed technique is its ability to provide effective automated control without receiving explicit information regarding either meals that the subject 12 has ingested or any other “feedforward” information, which is achieved in part by an adaptive aspect to operation of the controller 18 .
- the controller 18 is an electrical device with control circuitry that provides operating functionality as described herein.
- the controller 18 may be realized as a computerized device having computer instruction processing circuitry that executes one or more computer programs each including respective sets of computer instructions.
- the processing circuitry will generally include one or more processors along with memory and input/output circuitry coupled to the processor(s), where the memory stores computer program instructions and data and the input/output circuitry provides interface(s) to external devices such as the glucose sensor 16 and delivery device(s) 14 .
- the control system 10 is also able to operate in an offline manner in which it is used to provide delivery of insulin (and potentially glucagon as well) but not based on glucose levels reported by the sensor 16 .
- overall operation may be divided between online periods each including a succession of sampling intervals when a glucose signal (level) 19 is available, and offline periods each including a succession of sampling intervals when the glucose signal (level) 19 is either completely or only intermittently unavailable.
- online and “offline” for these periods.
- offline operation may be user-selected for some reason even when a glucose level signal 19 is available for use.
- User control inputs may be provided via a local or remote user interface of some type.
- the user interface may resemble that of conventional insulin pumps or similar devices, e.g., by including control buttons for commanding the delivery of a bolus and perhaps a small display.
- the system may have a wired or wireless interface to a remote device that may incorporate a fuller-function user interface, such as a smartphone or analogous personal computing device.
- the glucose sensor 16 may be absent, non-functioning, or not coupled to the subject 12 , with the result that the blood glucose signal 19 is not available to control automatic operation.
- the glucose level control system 10 is a personal device worn by a subject 12 for continual glucose control.
- the user and subject 12 are the same person.
- FIG. 2 shows the structure of the controller 18 . It includes four separate controllers, namely a glucagon controller 22 , basal insulin controller 24 , corrective insulin controller 26 , and priming insulin controller 28 .
- the basal insulin controller 24 includes a nominal rate controller 30 and a modulating controller 32 .
- the glucagon controller 22 generates a glucagon dose control signal 34 provided to a glucagon delivery device 14 - 1 .
- Respective outputs 36 - 40 from the controllers 24 - 28 are combined to form an overall insulin dose control signal 42 provided to insulin delivery device(s) 14 - 2 .
- the output signal 36 from the basal insulin controller 24 is formed by a combination of respective outputs of the nominal rate controller 30 and modulating controller 32 .
- the insulin delivery device(s) 14 - 2 may include devices tailored to deliver different types and/or quantities of insulin, with the exact configuration being known to and under the control of the controllers 24 - 28 .
- the collection of one or more insulin delivery devices 14 - 2 is referred below to in the singular as an insulin delivery device 14 - 2 .
- the inter-controller signals 44 enable communication of information from one controller, where the information is developed or generated, to another controller where the information is used for that controller's control function.
- the controllers 22 - 28 may be operated in either the online/automatic mode or in the offline mode.
- the corrective controller 26 regulates glucose level using a control scheme such as described in US patent publication 2008/0208113A1, the contents of which are incorporated by reference herein.
- the basal controller 24 and priming insulin controller 28 may perform adaptive automated control as described in international patent application publication WO 2012/058694 A2, the contents of which are incorporated by reference herein.
- the controllers 22 - 28 generally employ control methods or algorithms that include control parameters that are mathematically combined with reported glucose values to generate an output value that is converted (either directly or via additional conditioning) into the dose control signals 34 , 42 .
- control scheme described in US patent publication 2008/0208113A1 includes a generalized predictive control (GPC) method that incorporates a variety of control parameters.
- the control algorithms are generally adaptive, meaning that control parameters are dynamically adjusted during operation to reflect changing operating circumstances and a “learning” aspect—by monitoring its own operation, the algorithm adjusts its operation to be more specifically tailored to the individual user, enhancing the algorithm's effectiveness and reducing or avoiding a need for additional explicit input information about the user.
- input parameters 20 form part of the control parameters used by the control algorithm; other control parameters are internal parameters according to the specifics of the algorithm, and selected ones of those internal control parameters are dynamically adjusted to realize the adaptation of the control algorithm.
- One feature of operation is the ability of the controllers to learn from recent past periods of online operation and to use that learning during offline operation.
- a first method automatically calculates the correct size of a correction bolus of insulin at a time of receiving an isolated glucose measurement, the correction bolus then being administered by the system in response to a user control input.
- a second method automatically calculates the correct size of a meal bolus of insulin and administers it in response to a user control input. Both methods utilize information obtained during past periods of online operation to automatically calculate correct values, freeing the user of a need to make the calculation or provide a correction factor.
- the method for automatically calculating a correction bolus dose in real time during offline operation is achieved by invoking an online control algorithm individually on isolated glucose measurements as they are provided to the control system 10 during offline operation.
- isolated glucose measurements may be blood glucose (BG) measurements from a glucose meter of any kind or glucose measurements obtained from another glucose monitor of any kind, provided to the control system 10 via the user controls 23 .
- the automatic calculation of the correction bolus doses follows the same method described for continuous online control in the above-referenced US patent publication 2008/0208113A1, treating each isolated glucose measurement provided during offline operation as if it were a glucose value obtained from the glucose level signal 19 . Effectively, each correction bolus operation is a brief resumption of online control.
- Time gaps in glucose data are taken into account by the online algorithm in its calculations of the effective rate of change of glucose as well as the overall outstanding insulin accumulation when the online algorithm is invoked in real time around the isolated glucose measurements.
- the algorithm continues to mark the passage of time as a succession of sampling intervals in which it does not receive glucose sensor input and it does not generate regular correction doses of insulin. It continues to model the diminishing of on-board insulin level in the subject 12 over time, so that at any given time it has an accurate estimate of the future effect of previously administered insulin.
- the algorithm When the controller 18 receives an isolated glucose measurement from the user along with an instruction to generate a correction dose, the algorithm performs an interpolation between the current glucose measurement and the most recent glucose sample value (from a preceding period of online control or isolated glucose measurement) to obtain estimated glucose values for recent sampling intervals as needed for the algorithm's computations.
- the system may request user confirmation before delivering the automatically calculated correction bolus, while in other embodiments it may not request confirmation or there may be a configuration setting to control whether confirmation is requested. Similarly, the system may or may not disclose the dosing amount to the user, and/or may allow the user to modify the dosing amount (these behaviors also being configurable in one embodiment).
- FIG. 3 illustrates high-level operation of the method for automatically calculating a correction bolus dose.
- the controller 18 employs a control algorithm that includes (i) regularly administering correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject.
- this operation may be in accordance with the above-referenced US patent publication 2008/0208113A1.
- the controller 18 engages in offline operation that includes (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction bolus operations each including administering a correction bolus of that is calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the correction bolus operation.
- correction bolus operation is used for convenience; this operation may alternatively be referred to using the more general term “correction dosing operation.”
- the correction bolus may be calculated by the controller 18 during offline operation assuming a first target glucose level or range higher than a second target glucose level or range assumed during online operation. Additionally, the correction dose of insulin may be calculated by the controller 18 during periods when the counter-regulatory delivery channel or device 14 - 1 is unavailable, and assuming a first target glucose level or range higher than a second target glucose level or range assumed when the counter-regulatory delivery channel or device is available.
- FIGS. 4 - 7 show results of simulations illustrating the proposed automatic normalized correction bolus dose action when the controller 18 is offline, using arbitrary parameters in the control system 10 .
- these simulations also demonstrate the stability and added safety of this method, as it removes the vulnerability of the system that could arise from subjective dosing estimation by the user during isolated periods when the controller 18 is offline.
- the simulations in these figures use controller, glucose data, and blood-glucose (BG) data that may resemble data from an experiment in a clinical study.
- BG blood-glucose
- FIG. 4 shows a scenario in which regular online operation is occurring up to a time that a user provides a BG value BG 1 as an input that is ignored by the control system 10 , and then the control system 10 is taken offline.
- This simulation provides a reference online insulin response for comparison with responses when the control system 10 uses BG 1 to automatically calculate a correction bolus of insulin.
- the control system 10 administers a total bolus insulin of 13.25 U to counter the hyperglycemic excursion that is occurring at the time of the BG 1 .
- the euglycemic band between 70 and 120 is indicated by shading.
- FIGS. 5 - 7 show insulin responses when the method of FIG. 3 is used, specifically in these cases to respond to the user-entered BG 1 value.
- Such an automated BG-based correction bolus response replaces the conventional practice in which the user calculates insulin correction bolus doses during isolated offline periods based on what the user estimates to be their “correction factor”.
- a correction factor can be subjectively selected, and in not even be known to a newly diagnosed user.
- its use may put the control system 10 in jeopardy or in a vulnerable state if inappropriately estimated by the user, particularly if the value is excessive.
- user action is only required to obtain and enter BG values, an activity that is always necessary to determine correction doses if there is no automated sensing of glucose levels (e.g., during offline operation).
- FIG. 5 shows one simulation in which a correction bolus of insulin is automatically calculated by the control system 10 in response to user-entered BG 1 after an offline period of 30 minutes.
- the total correction insulin over the hyperglycemic excursion leading to BG 1 is 7.15 U, which is more conservative than the pure online response of FIG. 4 .
- a more realistic simulation might account for the period of offline operation prior to BG 1 by having the BG level drift higher.
- BG 1 were greater than 400
- total correction insulin that would be delivered is only 12.65 U, which is still more conservative than the pure online response in FIG. 4 and therefore safer, particularly because it inevitably comes later with BG already in severe hyperglycemia.
- the control system 10 may enforce an upper limit on the value of a BG measurement it will use, such as 400.
- the user interface might enforce this limit.
- FIGS. 4 and 5 also show automatic glucagon correction doses in response to BG 2 and BG 3 .
- This provides added safety by the system and is a response that is not available in usual care.
- FIGS. 6 and 7 show the correction bolus of insulin automatically calculated by the control system 10 in response to user-entered BG 1 after offline periods of 60 and 90 minutes, respectively.
- the latter case in essence shows the response when the hyperglycemic excursion occurs entirely while the control system 10 is offline.
- the total bolus insulin over the hyperglycemic excursion leading to BG 1 is 6.15 U and 4.1 U respectively, which in both cases is more conservative than the purely controller-based insulin response in FIG. 4 .
- a more realistic simulation would show a higher BG value at the time of the BG 1 sample.
- FIG. 8 provides data from a simulation using different controller and BG data, which is also used for illustration of the meal bolus method in the next section below, as well as for the superposition of the two methods also described below. Also, a longer overall period is shown.
- FIG. 8 shows a sample simulation illustrating the method of automatically calculating correction bolus doses in real time during offline operation (in this example, from 17:30 to 16:30 across two consecutive days) individually based on isolated glucose measurements that are provided to the control system 10 during online operation (e.g. blood glucose measurements from a glucose meter or glucose measurements obtained from another glucose monitor).
- the top panel shows the glucose trace (as black circles) during online operation and times of meals (indicated by black triangles), with additional glucose measurements (indicated by gray stars) that were provided by the user to the control system 10 during offline operation.
- the bottom panel shows automatically generated correction insulin doses as slender gray bars. Also shown are meal bolus doses indicated by isolated gray strikes with arrowheads—these are described in a separate section below.
- insulin doses include bolus and basal doses generated by the online algorithm as well as (potential) meal bolus doses
- insulin doses include algorithm-generated basal doses as well as automatically calculated correction bolus doses.
- Each correction bolus dose during offline operation is automatically calculated by invoking the online control algorithm individually on the isolated glucose measurements in real time as they are provided to the control system 10 , as described above.
- both online and offline periods are generally different from the arbitrarily chosen spans in this example, and each can contain intermittent segments of the other within its span.
- a method is also described for automatically calculating a meal bolus dose in real time during offline operation by an online control algorithm based on the prandial and post-prandial response(s) during preceding period(s) of online operation when a meal bolus was administered for a meal or snack of the corresponding kind and/or time interval of day (breakfast, lunch, or dinner).
- the automatic calculation from preceding period(s) of online operation could include multiple incidents of each kind of meal bolus dose (e.g. multiple days having occasions of breakfast, lunch, or dinner).
- the automatic calculation of the meal bolus doses during offline operation may follow the same method described in the above-referenced international patent application publication WO 2012/058694 A2 for its implementation during online operation, i.e. meal bolus doses are adapted based on online operation and in this case are issued in the same way during offline operation as they are during continual online operation.
- FIG. 9 illustrates high-level operation of the method for automatically calculating a meal bolus dose during offline operation.
- the controller 18 employs a control algorithm that (i) administers meal bolus doses of insulin in response to a meal bolus control input and automatically calculated by the controller 18 based on preceding meal bolus doses and corresponding prandial and post-prandial responses of the subject 12 as reflected in sampling of glucose levels via the glucose sensor and (ii) autonomously adjusts control parameters used to determine meal bolus dose size to tailor the control parameters to the subject.
- offline operation includes (iii) evolving a state of the control algorithm over time without sampling of glucose levels, and (iv) meal bolus operations each including administration of a meal bolus of insulin in response to the meal bolus control input and calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the meal bolus operation.
- the meal bolus may be administered in one continuous ejection or discharge from the insulin pump, or it may be administered as multiple ejections over a short period (e.g., split over consecutive sampling intervals).
- Some pumps enforce a limit for a single ejection, so if the bolus to be delivered exceeds that limit then it may be delivered using multiple ejections over a short period (e.g., split over consecutive sampling intervals).
- the term “meal bolus operation” is used for convenience; this operation may alternatively be referred to using the more general term “meal dosing operation.”
- FIG. 10 provides a sample illustration of the described method. This uses the controller and BG data that was also used for illustration of the correction bolus method in FIG. 8 . Note that the inherent learning and adjusting of meal bolus doses in this method can continually undergo online adjustments with more periods of online control.
- the system may or may not request user confirmation before delivering the automatically calculated meal bolus, may or may not disclose the dosing amount to the user, and may or may not allow the user to modify the dosing amount.
- FIG. 10 shows a sample simulation illustrating the method of automatically calculating meal bolus doses in real time during offline operation (in this example, from 17:30 to 16:30 across two consecutive days) based on meal bolus doses and their corresponding prandial and post-prandial responses during preceding online operation (in this example, from a preceding period of 18:00 to 17:30 across two consecutive days).
- the top panel shows the glucose trace (as black circles) during online operation and times of meals (indicated by black triangles).
- the bottom panel shows automatically generated insulin doses as slender gray bars, with meal bolus doses (as they are triggered or announced by the user) indicated by isolated gray strikes with arrowheads.
- insulin doses include correction boluses and basal doses generated by the online algorithm as well as meal bolus doses
- insulin doses include algorithm-generated basal doses and automatically calculated meal bolus doses.
- Each meal bolus dose during offline operation was automatically calculated by the online algorithm based on the prandial and post-prandial response(s) during preceding period(s) of online operation when a meal bolus was administered for a meal or snack of the corresponding kind and/or time interval of day (breakfast, lunch, or dinner).
- the automatic calculation from preceding period(s) of online operation could include multiple incidents of each kind of meal bolus dose (e.g. multiple days having multiple occasions of breakfast, lunch, or dinner).
- both online and offline periods can vary in span from their arbitrarily chosen spans in this example, and each can contain intermittent segments of the other within its span.
- the user may choose not to utilize the meal bolus dose option when in online operation, as the control algorithm is able to automatically respond to prandial or post-prandial glucose excursions when in online operation.
- the control algorithm is able to automatically respond to prandial or post-prandial glucose excursions when in online operation.
- an automatic online response will be absent or ineffective if the prandial or post-prandial period occurs when in offline operation. Therefore, good glycemic control generally requires using the meal bolus dose option around the times of food consumption during offline operation. Since the meal bolus dose is effectively adapted during online operation, it follows that in order to get optimal control when using it during offline operation, the user should occasionally, if not regularly, use the meal bolus dose option in online operation.
- Occasional utilization could be on the order of once per week for a couple of weeks for each kind and/or time interval of day (breakfast, lunch, or dinner), but could also be more or less frequent than that, and/or altogether on an irregular time basis.
- Such occasional online usage over time allows for repeated adaptations of the meal bolus dose, which essentially updates the meal bolus dose magnitude(s) to better suit the user's needs based on their own determinations of the relative size of meals.
- the meal bolus dose option may or may not be necessary for effective control under online operation, using it (at least occasionally) during online operation allows adapting the meal bolus dose magnitude(s) so as to be more effective when used in offline operation.
- FIG. 11 shows an example in which both the methods of (1) automatically calculating correction bolus doses of insulin and (2) automatically calculating meal bolus of insulin in real time during online operation are used together.
- This simulation uses the controller and BG data that was also used for illustrations of the correction bolus and meal bolus methods described above.
- control system 10 can, in a similar manner, automatically calculate in real time a correction bolus dose of a counter-regulatory agent (such as glucagon) during online operation.
- a counter-regulatory agent such as glucagon
- offline operation action around an isolated glucose measurement could include real-time doses of the counter-regulatory agent.
- the system can still issue a correction bolus of insulin in an independent manner, so that it can exercise both correction bolus kinds (insulin and glucagon) or one kind without the other.
- FIG. 12 shows an example, using glucagon as the counter-regulatory agent, in which the system automatically calculates both kinds of correction bolus doses (insulin and glucagon).
- the correction bolus doses of insulin are arbitrarily chosen to be at the same times as those in FIG. 8 , and correction bolus action of glucagon is illustrated in the simulation at around 00:30 on the second day, where a glucose measurement that is near the low end of normal range was provided to the control system 10 .
- the system could also respond with counter-regulatory correction bolus action for higher or lower glucose measurement, depending on each individual situation and the control algorithm used.
- the automatic calculation of the counter-regulatory correction bolus doses may follow the same method described for continuous online control in the above-referenced US patent publication 2008/0208113A1, treating the correction and meal bolus operations as brief resumption of online control as described above. Additionally, the system may include an ability to readily deliver a (default) preset counter-regulatory correction bolus (e.g. in cases of emergency). With these methods all superimposed as they are in FIG.
- periods of online operation include algorithm-generated correction bolus doses of insulin and glucagon, meal bolus doses of insulin, and basal doses of insulin, all automatically calculated by the controller 18 .
- control algorithm may allow the subject to issue a microburst or rescue dose of counter-regulatory agent, with a value of the microburst or rescue dose being calculated by the controller 18 .
- All of the methods described above could be used in the in-patient (e.g. critical care units or general wards, where the route of drug administration could vary and where dextrose is an example of a counter-regulatory agent) or out-patient settings and could be used in the context of an autonomous or semi-autonomous online glucose control system 10 (e.g. sensor-augmented infusion system).
- the methods could also be applied in online operation separately or in conjunction in various combinations. When employed in online operation, these methods could ultimately render obsolete notions of requiring the user (or care provider) to know and set control parameters such as insulin-to-carbohydrate ratios, correction factors (for both insulin or insulin-like agent and a counter-regulatory agent), as well as basal rates of insulin infusion.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Primary Health Care (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Apparatus and methods calculate and deliver doses of insulin and optionally glucagon into a subject. Online operation controls delivery of correction doses of insulin automatically in response to regular glucose measurements from a sensor, and offline operation calculates and delivers correction doses based on isolated glucose measurements and information gathered autonomously during preceding online operation. In another aspect, offline operation includes automatically calculating and administering meal doses based on information gathered autonomously during preceding periods of online operation. Both methods include generating relevant control parameters tailored to the individual and continually converged upon and potentially modulated during online operation. The control parameters are employed in real time during periods of offline operation to regulate glucose level without the need for user-provided control parameters such as correction factors and insulin-to-carbohydrate ratios.
Description
The invention was made with Government support under Contract No. DK085633 awarded by the National Institutes of Health. The Government has certain rights in the invention.
Standard-of-care insulin therapies for regulating blood glucose in diabetes typically involve either multiple daily subcutaneous injections or subcutaneous infusion with an insulin pump. Typically, combinations of basal and bolus insulin are administered to meet the subject's basal metabolic insulin requirement; correction bolus doses are administered to regulate hyperglycemia; and additional meal bolus doses are added to provide insulin for food consumption. In current usual care, a correction bolus of insulin that is typically administered to treat a hyperglycemic state is based on an estimate of the individual's so-called “correction factor(s)”, which relate how much insulin is estimated by the user to adequately compensate for different levels of hyperglycemia. Correction factors are heuristically estimated on an individual basis and are modified (essentially by trial-and-error) from time to time. This is similar to how basal rates of insulin are heuristically estimated on an individual basis to provide basal metabolic insulin requirements.
Similarly, meal bolus insulin doses taken around food consumption are also typically estimated heuristically on an individual basis based on the quantity and content (carbohydrate and other) of the food, in conjunction with a heuristic estimate of the individual's so-called “insulin-to-carbohydrate ratio(s)”, among other factors such as the time of the day, physical activity, health state, emotional state, etc. The right correction bolus doses, insulin basal rates, and meal bolus doses alike, are all essentially determined by trial-and-error experience and could vary significantly among individuals as well as for an individual over time; yet, they are all critical determinants of how well an individual is able to control their blood glucose. Dosing requirements are also subject to factors such as the time of the day, physical activity, health state, emotional state, etc., and could vary over periods of hours, days, or weeks due to transient changes (e.g. due to circadian hormonal fluctuations, current illness, physical activity, or emotional state) and/or periods of months or years due to developmental changes (e.g. due to hormonal changes that occur during puberty or menopause).
Disclosed herein are automated methods for calculating and delivering doses of insulin or insulin-like agents and/or a counter-regulatory agent such as glucagon or glucagon-like agents, infused into a subject via any of several routes including subcutaneously, intramuscularly, intraperitoneally, or intravenously. The methods adapt to an individual user and do not require inputs such as “correction factors” and “insulin-to-carbohydrate” factors.
A first disclosed method includes periods of online operation when a controller is operating to control the delivery of correction boluses of insulin automatically in response to regular glucose levels provided by a sensor at regular intervals (e.g., on the order of 1-15 minutes apart), also referred to as “sampling intervals”. Online operation of the controller refers to sampling intervals when there are a glucose measurements provided by the sensor and offline operation refers to sampling intervals when there are no glucose measurements provided by the sensor. The method further includes offline operation when a controller responds automatically to isolated glucose measurements (e.g., provided by the subject to the controller), using information that was gathered autonomously by the control system during preceding periods of online operation. A second disclosed method includes automatically calculating and administering meal bolus doses in response to meal announcements during periods of offline operation based on information that was gathered autonomously by the control system during preceding periods of online operation. The two methods involve autonomously generating relevant control parameters that are tailored to the individual and are continually converged upon and potentially modulated during periods of online operation. The control parameters are then employed in real time during periods of offline operation in order to regulate glucose levels without the need for the user to provide corresponding control parameters (e.g. insulin-to-carbohydrate ratios, or insulin correction factors). The methods may be used independently or together, and they may also be supplemented by analogous control methods for delivery of a counter-regulatory agent during offline operation, as described more below.
The foregoing and other objects, features and advantages will be apparent from the following description of particular embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views.
The disclosures of the following published patent documents are incorporated by reference herein:
US patent publication 2008/0208113 A1
PCT application publication WO 2012/058694 A2
US patent application publication 20130245547 A1
For online or autonomous operation, a glucose sensor 16 is operatively coupled to the subject 12 to continually sample a glucose level of the subject 12. Sensing may be accomplished in a variety of ways, generally involving some form of physical coupling 21 between the subject 12 and the glucose sensor 16. A controller 18 controls operation of the delivery device(s) 14 as a function of a glucose level signal 19 from the glucose sensor 16 and subject to programmed input parameters (PARAMS) 20 which may be provided by a user such as the subject 12. One input parameter for automatic operation is the weight of the subject 12. One feature of the disclosed technique is its ability to provide effective automated control without receiving explicit information regarding either meals that the subject 12 has ingested or any other “feedforward” information, which is achieved in part by an adaptive aspect to operation of the controller 18.
The controller 18 is an electrical device with control circuitry that provides operating functionality as described herein. In one embodiment, the controller 18 may be realized as a computerized device having computer instruction processing circuitry that executes one or more computer programs each including respective sets of computer instructions. In this case the processing circuitry will generally include one or more processors along with memory and input/output circuitry coupled to the processor(s), where the memory stores computer program instructions and data and the input/output circuitry provides interface(s) to external devices such as the glucose sensor 16 and delivery device(s) 14.
The control system 10 is also able to operate in an offline manner in which it is used to provide delivery of insulin (and potentially glucagon as well) but not based on glucose levels reported by the sensor 16. Thus, overall operation may be divided between online periods each including a succession of sampling intervals when a glucose signal (level) 19 is available, and offline periods each including a succession of sampling intervals when the glucose signal (level) 19 is either completely or only intermittently unavailable. The description below uses the terms “online” and “offline” for these periods. Also, offline operation may be user-selected for some reason even when a glucose level signal 19 is available for use.
User control inputs (USER CNTLs 23) may be provided via a local or remote user interface of some type. In one embodiment, the user interface may resemble that of conventional insulin pumps or similar devices, e.g., by including control buttons for commanding the delivery of a bolus and perhaps a small display. In other embodiments, the system may have a wired or wireless interface to a remote device that may incorporate a fuller-function user interface, such as a smartphone or analogous personal computing device. In offline mode, the glucose sensor 16 may be absent, non-functioning, or not coupled to the subject 12, with the result that the blood glucose signal 19 is not available to control automatic operation.
The description herein refers to a “user” as the source of the user control inputs 23. In one typical use, the glucose level control system 10 is a personal device worn by a subject 12 for continual glucose control. In this case the user and subject 12 are the same person. In other uses, there may be another person involved in the care of the subject 12 and providing control input, and in such a case that other person has the role of user.
Also shown in FIG. 2 are input/output signals of the various controllers, including the glucose level signal 19, parameters 20 and user inputs 23 as well as a set of inter-controller signals 44. The inter-controller signals 44 enable communication of information from one controller, where the information is developed or generated, to another controller where the information is used for that controller's control function.
The controllers 22-28 may be operated in either the online/automatic mode or in the offline mode. In the automated mode, the corrective controller 26 regulates glucose level using a control scheme such as described in US patent publication 2008/0208113A1, the contents of which are incorporated by reference herein. The basal controller 24 and priming insulin controller 28 may perform adaptive automated control as described in international patent application publication WO 2012/058694 A2, the contents of which are incorporated by reference herein. The controllers 22-28 generally employ control methods or algorithms that include control parameters that are mathematically combined with reported glucose values to generate an output value that is converted (either directly or via additional conditioning) into the dose control signals 34, 42. For example, the control scheme described in US patent publication 2008/0208113A1 includes a generalized predictive control (GPC) method that incorporates a variety of control parameters. The control algorithms are generally adaptive, meaning that control parameters are dynamically adjusted during operation to reflect changing operating circumstances and a “learning” aspect—by monitoring its own operation, the algorithm adjusts its operation to be more specifically tailored to the individual user, enhancing the algorithm's effectiveness and reducing or avoiding a need for additional explicit input information about the user. It should be noted that the input parameters 20 form part of the control parameters used by the control algorithm; other control parameters are internal parameters according to the specifics of the algorithm, and selected ones of those internal control parameters are dynamically adjusted to realize the adaptation of the control algorithm.
One feature of operation is the ability of the controllers to learn from recent past periods of online operation and to use that learning during offline operation. Specifically, described below are two methods that are usable independently or together in offline operation. A first method automatically calculates the correct size of a correction bolus of insulin at a time of receiving an isolated glucose measurement, the correction bolus then being administered by the system in response to a user control input. A second method automatically calculates the correct size of a meal bolus of insulin and administers it in response to a user control input. Both methods utilize information obtained during past periods of online operation to automatically calculate correct values, freeing the user of a need to make the calculation or provide a correction factor.
I. Automatically Calculated Correction Bolus During Periods of Offline Operation
The method for automatically calculating a correction bolus dose in real time during offline operation is achieved by invoking an online control algorithm individually on isolated glucose measurements as they are provided to the control system 10 during offline operation. These isolated glucose measurements may be blood glucose (BG) measurements from a glucose meter of any kind or glucose measurements obtained from another glucose monitor of any kind, provided to the control system 10 via the user controls 23. The automatic calculation of the correction bolus doses follows the same method described for continuous online control in the above-referenced US patent publication 2008/0208113A1, treating each isolated glucose measurement provided during offline operation as if it were a glucose value obtained from the glucose level signal 19. Effectively, each correction bolus operation is a brief resumption of online control. Time gaps in glucose data are taken into account by the online algorithm in its calculations of the effective rate of change of glucose as well as the overall outstanding insulin accumulation when the online algorithm is invoked in real time around the isolated glucose measurements. In particular, during offline operation the algorithm continues to mark the passage of time as a succession of sampling intervals in which it does not receive glucose sensor input and it does not generate regular correction doses of insulin. It continues to model the diminishing of on-board insulin level in the subject 12 over time, so that at any given time it has an accurate estimate of the future effect of previously administered insulin. When the controller 18 receives an isolated glucose measurement from the user along with an instruction to generate a correction dose, the algorithm performs an interpolation between the current glucose measurement and the most recent glucose sample value (from a preceding period of online control or isolated glucose measurement) to obtain estimated glucose values for recent sampling intervals as needed for the algorithm's computations.
In one embodiment the system may request user confirmation before delivering the automatically calculated correction bolus, while in other embodiments it may not request confirmation or there may be a configuration setting to control whether confirmation is requested. Similarly, the system may or may not disclose the dosing amount to the user, and/or may allow the user to modify the dosing amount (these behaviors also being configurable in one embodiment).
At 52, the controller 18 engages in offline operation that includes (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction bolus operations each including administering a correction bolus of that is calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the correction bolus operation. In this description, the term “correction bolus operation” is used for convenience; this operation may alternatively be referred to using the more general term “correction dosing operation.”
The correction bolus may be calculated by the controller 18 during offline operation assuming a first target glucose level or range higher than a second target glucose level or range assumed during online operation. Additionally, the correction dose of insulin may be calculated by the controller 18 during periods when the counter-regulatory delivery channel or device 14-1 is unavailable, and assuming a first target glucose level or range higher than a second target glucose level or range assumed when the counter-regulatory delivery channel or device is available.
Additional details of the method for automatically calculating a correction bolus dose during offline operation and its effects are now provided with reference to data generated by simulations of operation based on assumed characteristics of a subject or user.
During online periods in the simulation of FIG. 8 , insulin doses include bolus and basal doses generated by the online algorithm as well as (potential) meal bolus doses, whereas during offline operation, insulin doses include algorithm-generated basal doses as well as automatically calculated correction bolus doses. Each correction bolus dose during offline operation is automatically calculated by invoking the online control algorithm individually on the isolated glucose measurements in real time as they are provided to the control system 10, as described above. In real operation, both online and offline periods are generally different from the arbitrarily chosen spans in this example, and each can contain intermittent segments of the other within its span.
II. Automatically Calculated Meal Bolus Dose During Periods of Offline Control
A method is also described for automatically calculating a meal bolus dose in real time during offline operation by an online control algorithm based on the prandial and post-prandial response(s) during preceding period(s) of online operation when a meal bolus was administered for a meal or snack of the corresponding kind and/or time interval of day (breakfast, lunch, or dinner). The automatic calculation from preceding period(s) of online operation could include multiple incidents of each kind of meal bolus dose (e.g. multiple days having occasions of breakfast, lunch, or dinner). The automatic calculation of the meal bolus doses during offline operation may follow the same method described in the above-referenced international patent application publication WO 2012/058694 A2 for its implementation during online operation, i.e. meal bolus doses are adapted based on online operation and in this case are issued in the same way during offline operation as they are during continual online operation.
At 62, offline operation includes (iii) evolving a state of the control algorithm over time without sampling of glucose levels, and (iv) meal bolus operations each including administration of a meal bolus of insulin in response to the meal bolus control input and calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the meal bolus operation. The meal bolus may be administered in one continuous ejection or discharge from the insulin pump, or it may be administered as multiple ejections over a short period (e.g., split over consecutive sampling intervals). Some pumps enforce a limit for a single ejection, so if the bolus to be delivered exceeds that limit then it may be delivered using multiple ejections over a short period (e.g., split over consecutive sampling intervals). In this description, the term “meal bolus operation” is used for convenience; this operation may alternatively be referred to using the more general term “meal dosing operation.”
More specifically, FIG. 10 shows a sample simulation illustrating the method of automatically calculating meal bolus doses in real time during offline operation (in this example, from 17:30 to 16:30 across two consecutive days) based on meal bolus doses and their corresponding prandial and post-prandial responses during preceding online operation (in this example, from a preceding period of 18:00 to 17:30 across two consecutive days). The top panel shows the glucose trace (as black circles) during online operation and times of meals (indicated by black triangles). The bottom panel shows automatically generated insulin doses as slender gray bars, with meal bolus doses (as they are triggered or announced by the user) indicated by isolated gray strikes with arrowheads. During online operation, insulin doses include correction boluses and basal doses generated by the online algorithm as well as meal bolus doses, whereas during offline operation, insulin doses include algorithm-generated basal doses and automatically calculated meal bolus doses. Each meal bolus dose during offline operation was automatically calculated by the online algorithm based on the prandial and post-prandial response(s) during preceding period(s) of online operation when a meal bolus was administered for a meal or snack of the corresponding kind and/or time interval of day (breakfast, lunch, or dinner). The automatic calculation from preceding period(s) of online operation could include multiple incidents of each kind of meal bolus dose (e.g. multiple days having multiple occasions of breakfast, lunch, or dinner). The inherent learning and adjusting of meal bolus doses in this method can continually undergo offline adjustments with more periods of online control. Also, both online and offline periods can vary in span from their arbitrarily chosen spans in this example, and each can contain intermittent segments of the other within its span.
Note that the user may choose not to utilize the meal bolus dose option when in online operation, as the control algorithm is able to automatically respond to prandial or post-prandial glucose excursions when in online operation. However, such an automatic online response will be absent or ineffective if the prandial or post-prandial period occurs when in offline operation. Therefore, good glycemic control generally requires using the meal bolus dose option around the times of food consumption during offline operation. Since the meal bolus dose is effectively adapted during online operation, it follows that in order to get optimal control when using it during offline operation, the user should occasionally, if not regularly, use the meal bolus dose option in online operation. Occasional utilization could be on the order of once per week for a couple of weeks for each kind and/or time interval of day (breakfast, lunch, or dinner), but could also be more or less frequent than that, and/or altogether on an irregular time basis. Such occasional online usage over time allows for repeated adaptations of the meal bolus dose, which essentially updates the meal bolus dose magnitude(s) to better suit the user's needs based on their own determinations of the relative size of meals. In summary, while the meal bolus dose option may or may not be necessary for effective control under online operation, using it (at least occasionally) during online operation allows adapting the meal bolus dose magnitude(s) so as to be more effective when used in offline operation.
Superposition of the Two Methods
Other Control Aspects
Independently, the control system 10 can, in a similar manner, automatically calculate in real time a correction bolus dose of a counter-regulatory agent (such as glucagon) during online operation. With a counter-regulatory agent being available for use by the control system 10, offline operation action around an isolated glucose measurement could include real-time doses of the counter-regulatory agent. The system can still issue a correction bolus of insulin in an independent manner, so that it can exercise both correction bolus kinds (insulin and glucagon) or one kind without the other.
In both the online and offline operations, the control algorithm may allow the subject to issue a microburst or rescue dose of counter-regulatory agent, with a value of the microburst or rescue dose being calculated by the controller 18.
All of the methods described above could be used in the in-patient (e.g. critical care units or general wards, where the route of drug administration could vary and where dextrose is an example of a counter-regulatory agent) or out-patient settings and could be used in the context of an autonomous or semi-autonomous online glucose control system 10 (e.g. sensor-augmented infusion system). The methods could also be applied in online operation separately or in conjunction in various combinations. When employed in online operation, these methods could ultimately render obsolete notions of requiring the user (or care provider) to know and set control parameters such as insulin-to-carbohydrate ratios, correction factors (for both insulin or insulin-like agent and a counter-regulatory agent), as well as basal rates of insulin infusion.
While various embodiments of the invention have been particularly shown and described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (40)
1. A glucose level control system, comprising:
a glucose sensor operative to continually measure a glucose level of a subject and generate a corresponding glucose level signal;
an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller having online operation and offline operation to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, online operation employing a control algorithm including (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on the isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the correction dosing operation.
2. A glucose level control system according to claim 1 , wherein the control algorithm employs regular periodic sampling intervals, and wherein evolving the control algorithm during the offline operation includes updating time effects of insulin previously administered to the subject.
3. A glucose level control system according to claim 2 , wherein each correction dose during the offline operation includes calculating estimated glucose levels for immediately preceding offline sampling intervals using interpolation between a current isolated glucose measurement and a sample of glucose level from a most recent period of online operation.
4. A glucose level control system according to claim 1 , wherein the correction dose is calculated by the controller during the offline operation assuming a first target glucose level or range higher than a second target glucose level or range assumed during online operation.
5. A glucose level control system according to claim 1 , wherein the isolated glucose measurement is provided to the controller via a user interface used by the subject, and wherein each correction dosing operation includes use of one or more user interface functions selected from (i) the subject confirming that the correction dose is to be delivered, (ii) displaying the value of the correction dose to the subject, and (iii) accepting a modified value from the subject for use as the correction dose instead of the correction dose calculated by the controller.
6. A glucose level control system according to claim 1 , wherein online operation of the control algorithm further includes regular administration of correction doses of a counter-regulatory agent based on the control parameters of the control algorithm and the regular periodic sampling of glucose levels, and wherein the offline operation further includes counter-regulatory agent dosing operations each including administration of a dose of a counter-regulatory agent in response to a second isolated glucose measurement provided to the controller and calculated by the controller based on the second isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the counter-regulatory agent dosing operation.
7. A glucose level control system according to claim 6 , wherein the correction dose of insulin is calculated by the controller during periods when a counter-regulatory delivery channel or device is unavailable and assuming a first target glucose level or range higher than a second target glucose level or range assumed when the counter-regulatory delivery channel or device is available.
8. A glucose level control system according to claim 1 , wherein in both the online and offline operations, the control algorithm allows the subject to issue a microburst or rescue dose of counter-regulatory agent, a value of the microburst or rescue dose being calculated by the controller.
9. A glucose level control system according to claim 1 , wherein online operation of the control algorithm includes (v) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in the sampling of glucose levels via the glucose sensor and (vi) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, and wherein offline operation including meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on a second isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the meal dosing operation.
10. A method of operating a controller for a glucose level control system having a glucose sensor and an insulin delivery device, the glucose sensor being operative to continually measure a glucose level of a subject and generate a corresponding glucose level signal, the insulin delivery device being operative in response to an insulin dose control signal to infuse insulin into the subject, comprising:
performing online operation employing a control algorithm including (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject; and
performing offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on the isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the correction dosing operation.
11. A method according to claim 10 , wherein the control algorithm employs regular periodic sampling intervals, and wherein evolving the control algorithm during the offline operation includes updating time effects of insulin previously administered to the subject.
12. A method according to claim 11 , wherein each correction dose during the offline operation includes calculating estimated glucose levels for immediately preceding offline sampling intervals using interpolation between a current isolated glucose measurement and a sample of glucose level from a most recent period of online operation.
13. A method according to claim 10 , wherein the correction dose is calculated by the controller during the offline operation assuming a first target glucose level or range higher than a second target glucose level or range assumed during online operation.
14. A method according to claim 10 , wherein the isolated glucose measurement is provided to the controller via a user interface used by the subject, and wherein each correction dosing operation includes use of one or more user interface functions selected from (i) the subject confirming that the correction dose is to be delivered, (ii) displaying a value of the correction dose to the subject, and (iii) accepting a modified value from the subject for use as the correction dose instead of the correction dose calculated by the controller.
15. A method according to claim 10 , wherein online operation of the control algorithm further includes regular administration of correction doses of a counter-regulatory agent based on the control parameters of the control algorithm and the regular periodic sampling of glucose levels, and wherein the offline operation further includes counter-regulatory agent dosing operations each including administration of a correction dose of a counter-regulatory agent in response to a second isolated glucose measurement provided to the controller and calculated by the controller based on the second isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the counter-regulatory agent dosing operation.
16. A method according to claim 15 , wherein the correction dose of insulin is calculated by the controller during periods when a counter-regulatory delivery channel or device is unavailable and assuming a first target glucose level or range higher than a second target glucose level or range assumed when the counter-regulatory delivery channel or device is available.
17. A method according to claim 10 , wherein in both the online and offline operations, the control algorithm allows the subject to issue a microburst or rescue dose of counter-regulatory agent, a value of the microburst or rescue dose being calculated by the controller.
18. A method according to claim 10 , wherein online operation of the control algorithm includes (v) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in the sampling of glucose levels via the glucose sensor and (vi) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, and wherein offline operation including meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on a second isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the meal dosing operation.
19. A glucose level control system, comprising:
a glucose sensor operative to continually measure glucose level of a subject and generate a corresponding glucose level signal;
an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller having online operation and offline operation to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, online operation employing a control algorithm including (i) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in sampling of glucose levels via the glucose sensor and (ii) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels, and (iv) meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on an isolated glucose measurement, the control parameters, and a state of the control algorithm as evolved at the time of the meal dosing operation.
20. A glucose level control system according to claim 19 , wherein online operation of the control algorithm further includes (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject, and wherein the offline operation further includes (iii) evolving the state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to a second isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on the second isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the correction dosing operation.
21. A controller for use in a glucose level control system having an insulin delivery device and a glucose sensor, the controller comprising:
processing circuitry including one or more processors;
memory; and
input/output circuitry,
the input/output circuitry providing respective interfaces to the insulin delivery device and the glucose sensor (1) to convey an insulin dose control signal to the insulin delivery device for controlling infusion of insulin into a subject, and (2) to receive a glucose level signal from the glucose sensor indicating a glucose level of the subject,
the memory storing computer program instructions executed by the processors to provide online operation and offline operation of the glucose level control system to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, the online operation employing a control algorithm including (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on (i) the isolated glucose measurement, (ii) the control parameters, and (iii) the state of the control algorithm as evolved at the time of the correction dosing operation.
22. The controller of claim 21 , wherein the control algorithm employs regular periodic sampling intervals, and wherein evolving the control algorithm during the offline operation includes updating time effects of insulin previously administered to the subject.
23. The controller of claim 22 , wherein each correction dose during the offline operation includes calculating estimated glucose levels for immediately preceding offline sampling intervals using interpolation between a current isolated glucose measurement and a sample of glucose level from a most recent period of online operation.
24. The controller of claim 21 , wherein the correction dose is calculated by the controller during the offline operation assuming a first target glucose level or range higher than a second target glucose level or range assumed during online operation.
25. The controller of claim 21 , wherein the isolated glucose measurement is provided to the controller via a user interface used by the subject, and wherein each correction dosing operation includes use of one or more user interface functions selected from (i) the subject confirming that the correction dose is to be delivered, (ii) displaying a value of the correction dose to the subject, and (iii) accepting a modified value from the subject for use as the correction dose instead of the correction dose calculated by the controller.
26. The controller of claim 21 , wherein online operation of the control algorithm further includes regular administration of correction doses of a counter-regulatory agent based on the control parameters of the control algorithm and the regular periodic sampling of glucose levels, and wherein the offline operation further includes counter-regulatory agent dosing operations each including administration of a dose of a counter-regulatory agent in response to a second isolated glucose measurement provided to the controller and calculated by the controller based on the second isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the counter-regulatory agent dosing operation.
27. The controller of claim 26 , wherein the correction dose of insulin is calculated by the controller during periods when a counter-regulatory delivery channel or device is unavailable and assuming a first target glucose level or range higher than a second target glucose level or range assumed when the counter-regulatory delivery channel or device is available.
28. The controller of claim 21 , wherein in both the online and offline operations, the control algorithm allows the subject to issue a microburst or rescue dose of counter-regulatory agent, a value of the microburst or rescue dose being calculated by the controller.
29. The controller of claim 21 , wherein online operation of the control algorithm includes (v) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in the sampling of glucose levels via the glucose sensor and (vi) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, and wherein offline operation including meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on the control parameters and the state of the control algorithm as evolved at the time of the meal dosing operation.
30. A method of operating a controller in a glucose level control system having a glucose sensor and an insulin delivery device, the controller having respective interfaces to the insulin delivery device and the glucose sensor (1) to convey an insulin dose control signal to the insulin delivery device for controlling infusion of insulin into a subject, and (2) to receive a glucose level signal from the glucose sensor indicating a glucose level of the subject, the method comprising:
performing online operation employing a control algorithm including (i) regularly administering correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels of the subject via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject; and
performing offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on (i) the isolated glucose measurement, (ii) the control parameters, and (iii) the state of the control algorithm as evolved at the time of the correction dosing operation.
31. The method of claim 30 , wherein the control algorithm employs regular periodic sampling intervals, and wherein evolving the control algorithm during the offline operation includes updating time effects of insulin previously administered to the subject.
32. The method of claim 31 , wherein each correction dose during the offline operation includes calculating estimated glucose levels for immediately preceding offline sampling intervals using interpolation between a current isolated glucose measurement and a sample of glucose level from a most recent period of online operation.
33. The method of claim 30 , wherein the correction dose is calculated by the controller during the offline operation assuming a first target glucose level or range higher than a second target glucose level or range assumed during online operation.
34. The method of claim 30 , wherein the isolated glucose measurement is provided to the controller via a user interface used by the subject, and wherein each correction dosing operation includes use of one or more user interface functions selected from (i) the subject confirming that the correction dose is to be delivered, (ii) displaying a value of the correction dose to the subject, and (iii) accepting a modified value from the subject for use as the correction dose instead of the correction dose calculated by the controller.
35. The method of claim 30 , wherein online operation of the control algorithm further includes regular administration of correction doses of a counter-regulatory agent based on the control parameters of the control algorithm and the regular periodic sampling of glucose levels, and wherein the offline operation further includes counter-regulatory agent dosing operations each including administration of a correction dose of a counter-regulatory agent in response to a second isolated glucose measurement provided to the controller and calculated by the controller based on the second isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the counter-regulatory agent dosing operation.
36. The method of claim 35 , wherein the correction dose of insulin is calculated by the controller during periods when a counter-regulatory delivery channel or device is unavailable and assuming a first target glucose level or range higher than a second target glucose level or range assumed when the counter-regulatory delivery channel or device is available.
37. The method of claim 30 , wherein in both the online and offline operations, the control algorithm allows the subject to issue a microburst or rescue dose of counter-regulatory agent, a value of the microburst or rescue dose being calculated by the controller.
38. The method of claim 30 , wherein online operation of the control algorithm includes (v) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in the sampling of glucose levels via the glucose sensor and (vi) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, and wherein offline operation including meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on a second isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the meal dosing operation.
39. A controller for use in a glucose level control system having an insulin delivery device and a glucose sensor, the controller comprising:
processing circuitry including one or more processors;
memory; and
input/output circuitry,
the input/output circuitry providing respective interfaces to the insulin delivery device and the glucose sensor (1) to convey an insulin dose control signal to the insulin delivery device for controlling infusion of insulin into a subject, and (2) to receive a glucose level signal from the glucose sensor indicating a glucose level of the subject,
the memory storing computer program instructions executed by the processors to provide online operation and offline operation of the glucose level control system to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, online operation employing a control algorithm including (i) administration of meal doses of insulin in response to a meal dose control input and automatically calculated by the controller based on preceding meal doses and corresponding prandial and post-prandial responses of the subject as reflected in sampling of glucose levels via the glucose sensor and (ii) autonomously adjusting control parameters used to determine meal dose size to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels, and (iv) meal dosing operations each including administration of a meal dose of insulin in response to the meal dose control input and calculated by the controller based on the control parameters and the state of the control algorithm as evolved at the time of the meal dosing operation.
40. The controller of claim 39 , wherein online operation of the control algorithm further includes (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject, and wherein the offline operation further includes (iii) evolving the state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on the isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the correction dosing operation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/313,401 USRE50075E1 (en) | 2014-01-31 | 2021-05-06 | Glucose level control system with offline control based on preceding periods of online control |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461933996P | 2014-01-31 | 2014-01-31 | |
PCT/US2015/012861 WO2015116524A1 (en) | 2014-01-31 | 2015-01-26 | Offline glucose control based on preceding periods |
US15/221,871 US10543313B2 (en) | 2014-01-31 | 2016-07-28 | Glucose level control system with offline control based on preceding periods of online control |
US17/313,401 USRE50075E1 (en) | 2014-01-31 | 2021-05-06 | Glucose level control system with offline control based on preceding periods of online control |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/012861 Continuation WO2015116524A1 (en) | 2014-01-31 | 2015-01-26 | Offline glucose control based on preceding periods |
US15/221,871 Reissue US10543313B2 (en) | 2014-01-31 | 2016-07-28 | Glucose level control system with offline control based on preceding periods of online control |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE50075E1 true USRE50075E1 (en) | 2024-08-13 |
Family
ID=53757655
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/221,871 Ceased US10543313B2 (en) | 2014-01-31 | 2016-07-28 | Glucose level control system with offline control based on preceding periods of online control |
US17/313,401 Active 2036-01-17 USRE50075E1 (en) | 2014-01-31 | 2021-05-06 | Glucose level control system with offline control based on preceding periods of online control |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/221,871 Ceased US10543313B2 (en) | 2014-01-31 | 2016-07-28 | Glucose level control system with offline control based on preceding periods of online control |
Country Status (10)
Country | Link |
---|---|
US (2) | US10543313B2 (en) |
EP (2) | EP4091541A1 (en) |
JP (1) | JP6243546B2 (en) |
CN (2) | CN112515665B (en) |
AU (2) | AU2015211258A1 (en) |
CA (1) | CA2938078C (en) |
DK (1) | DK3089667T3 (en) |
IL (1) | IL246934B (en) |
MX (2) | MX373076B (en) |
WO (1) | WO2015116524A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2755497T3 (en) | 2010-10-31 | 2020-04-22 | Univ Boston | Blood glucose monitoring system |
CN112515665B (en) | 2014-01-31 | 2024-03-29 | 波士顿大学董事会 | Blood glucose level control system |
US9629901B2 (en) * | 2014-07-01 | 2017-04-25 | Bigfoot Biomedical, Inc. | Glucagon administration system and methods |
US9943645B2 (en) * | 2014-12-04 | 2018-04-17 | Medtronic Minimed, Inc. | Methods for operating mode transitions and related infusion devices and systems |
WO2017027459A1 (en) | 2015-08-07 | 2017-02-16 | Trustees Of Boston University | Glucose control system with automatic adaptation of glucose target |
US11107566B2 (en) * | 2016-09-30 | 2021-08-31 | Novo Nordisk A/S | Systems and methods for communicating a dose history representing an average and a variability of a distribution of medicament injections |
US11147920B2 (en) * | 2017-04-18 | 2021-10-19 | Lifescan Ip Holdings, Llc | Diabetes management system with automatic basal and manual bolus insulin control |
CN110582231B (en) | 2017-05-05 | 2023-05-16 | 伊莱利利公司 | Closed-loop control of physiological glucose |
GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
AU2018388898A1 (en) | 2017-12-21 | 2020-06-11 | Ypsomed Ag | Closed loop control of physiological glucose |
JP7124120B2 (en) | 2018-05-04 | 2022-08-23 | インスレット コーポレイション | Safety Constraints for Control Algorithm-Based Drug Delivery Systems |
CA3103479A1 (en) | 2018-06-22 | 2019-12-26 | Eli Lilly And Company | Insulin and pramlintide delivery systems, methods, and devices |
US11071821B2 (en) * | 2018-09-28 | 2021-07-27 | Medtronic Minimed, Inc. | Insulin infusion device with efficient confirmation routine for blood glucose measurements |
JP2022541492A (en) | 2019-07-16 | 2022-09-26 | ベータ バイオニクス,インコーポレイテッド | blood sugar control system |
US11957876B2 (en) | 2019-07-16 | 2024-04-16 | Beta Bionics, Inc. | Glucose control system with automated backup therapy protocol generation |
DE112020003392T5 (en) | 2019-07-16 | 2022-05-19 | Beta Bionics, Inc. | BLOOD SUGAR CONTROL SYSTEM |
AU2020356952A1 (en) | 2019-10-04 | 2022-04-14 | Beta Bionics, Inc. | Blood glucose control system |
CN115004311A (en) * | 2019-12-20 | 2022-09-02 | 医科达股份有限公司 | Adaptive dose accumulation algorithm |
USD1032623S1 (en) | 2020-03-10 | 2024-06-25 | Beta Bionics, Inc. | Display screen with animated graphical user interface |
US11278661B2 (en) | 2020-03-10 | 2022-03-22 | Beta Bionics, Inc. | Infusion system and components thereof |
USD1032624S1 (en) | 2020-03-10 | 2024-06-25 | Beta Bionics, Inc. | Display screen with animated graphical user interface |
US20220199218A1 (en) | 2020-12-07 | 2022-06-23 | Beta Bionics, Inc. | Ambulatory medicament pump with integrated medicament ordering interface |
US20220265143A1 (en) | 2020-12-07 | 2022-08-25 | Beta Bionics, Inc. | Ambulatory medicament pumps with selective alarm muting |
US20220188388A1 (en) | 2020-12-07 | 2022-06-16 | Beta Bionics, Inc. | Ambulatory medicament pump with safe access control |
US11497852B2 (en) | 2020-12-21 | 2022-11-15 | Beta Bionics, Inc. | Ambulatory medicament device with power saving mode |
CN113598763B (en) * | 2021-08-05 | 2024-10-18 | 重庆大学 | Noninvasive blood glucose detection device and method based on MIC-PCA-NARX correction algorithm |
WO2023070253A1 (en) * | 2021-10-25 | 2023-05-04 | Medtrum Technologies Inc. | Closed-loop artificial pancreas insulin infusion control system |
Citations (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4280494A (en) | 1979-06-26 | 1981-07-28 | Cosgrove Robert J Jun | System for automatic feedback-controlled administration of drugs |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
JPH03500129A (en) | 1987-08-28 | 1991-01-17 | リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ | Metabolic sensors for drug delivery systems |
US5665065A (en) | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
CA2365316A1 (en) | 1999-04-15 | 2000-10-26 | William G. O'brien | Portable remote patient telemonitoring system |
JP2001204817A (en) | 1999-11-18 | 2001-07-31 | Roche Diagnostics Gmbh | System for extrapolation of glucose concentration |
JP2003079723A (en) | 2001-07-31 | 2003-03-18 | F Hoffmann-La Roche Ag | Diabetes management device |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6572542B1 (en) | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
WO2004006982A2 (en) | 2002-07-15 | 2004-01-22 | Insulet Corporation | Self-contained, automatic transcutaneous physiologic sensing system |
JP2004502474A (en) | 2000-02-10 | 2004-01-29 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | Apparatus and method for administering a proper amount of a hormone that regulates blood glucose in a patient |
US20040028707A1 (en) | 2001-06-29 | 2004-02-12 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
US20040034295A1 (en) | 2000-09-26 | 2004-02-19 | Marcos Salganicoff | Method and apparatus for real-time estimation and control of physiological parameters |
US20040147872A1 (en) | 1999-04-30 | 2004-07-29 | Medtronic, Inc. | Closed loop medicament pump |
WO2004084820A2 (en) | 2003-03-19 | 2004-10-07 | Harry Hebblewhite | Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
US20040253736A1 (en) | 2003-06-06 | 2004-12-16 | Phil Stout | Analytical device with prediction module and related methods |
EP1575656A1 (en) | 2002-10-11 | 2005-09-21 | Becton, Dickinson and Company | Insulin delivery system with sensor |
US20050272640A1 (en) | 2004-05-13 | 2005-12-08 | Doyle Francis J Iii | Method and apparatus for glucose control and insulin dosing for diabetics |
WO2006124716A2 (en) | 2005-05-13 | 2006-11-23 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
US20060276771A1 (en) | 2005-06-06 | 2006-12-07 | Galley Paul J | System and method providing for user intervention in a diabetes control arrangement |
US20060272652A1 (en) * | 2005-06-03 | 2006-12-07 | Medtronic Minimed, Inc. | Virtual patient software system for educating and treating individuals with diabetes |
CN1973768A (en) | 2005-11-28 | 2007-06-06 | 中国科学院电子学研究所 | Non-invasive blood sugar instrument for closed-loop insulin injection |
JP2007529241A (en) | 2004-03-08 | 2007-10-25 | ディセトロニック・ライセンシング・アクチェンゲゼルシャフト | Method and apparatus for calculating bolus amount |
EP1860583A2 (en) | 2006-05-24 | 2007-11-28 | Sysmex Corporation | Simulation system of function of biological organ |
US7347836B2 (en) | 1992-09-09 | 2008-03-25 | Smiths Medical, Inc. | Drug pump systems and methods |
WO2008057384A2 (en) | 2006-11-02 | 2008-05-15 | The University Of North Carolina At Chapel Hill | Methods and systems for determining an intravenous insulin infusion rate |
US20080154187A1 (en) | 2006-12-21 | 2008-06-26 | Lifescan, Inc. | Malfunction detection in infusion pumps |
US20080183060A1 (en) | 2007-01-31 | 2008-07-31 | Steil Garry M | Model predictive method and system for controlling and supervising insulin infusion |
WO2008114254A1 (en) | 2007-03-19 | 2008-09-25 | Medingo Ltd. | User interface for selecting bolus doses in a drug delivery device |
US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
WO2008157780A1 (en) | 2007-06-21 | 2008-12-24 | University Of Virginia Patent Foundation | Lqg artificial pancreas control system and related method |
US20080319384A1 (en) | 2007-06-25 | 2008-12-25 | Medingo, Ltd. | Tailored Basal Insulin Delivery System and Method |
US20090006061A1 (en) | 2007-06-27 | 2009-01-01 | Roche Diagnostics Operations, Inc. | System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof |
CN201186082Y (en) | 2008-05-05 | 2009-01-28 | 王安宇 | Intelligent input mechanism for insulins and glucose |
US7491187B2 (en) | 2002-03-22 | 2009-02-17 | K.U. Leuven Research & Development | Automatic infusion system based on an adaptive patient model |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US20090177154A1 (en) | 2008-01-08 | 2009-07-09 | Michael Blomquist | Insulin pump with convenience features |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US20100057057A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Closed Loop Control And Signal Attenuation Detection |
US20100082167A1 (en) | 2007-04-19 | 2010-04-01 | Disetronic Licensing Ag | Method for setting a basal rate profile for an insulin pump |
US20100125241A1 (en) | 2008-11-17 | 2010-05-20 | Disetronic Licensing, Ag | Prandial Blood Glucose Excursion Optimization Method Via Computation of Time-Varying Optimal Insulin Profiles and System Thereof |
US20100145262A1 (en) | 2007-05-03 | 2010-06-10 | Novo Nordisk A/S | Safety system for insulin delivery advisory algorithms |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
CN101795623A (en) | 2007-09-07 | 2010-08-04 | 泰尔茂株式会社 | Blood sugar measuring device |
CN101821741A (en) | 2007-06-27 | 2010-09-01 | 霍夫曼-拉罗奇有限公司 | Medical diagnosis, therapy, and prognosis system for invoked events and method thereof |
US20100256466A1 (en) | 2009-04-02 | 2010-10-07 | Avraham Shekalim | Metabolite Management System |
US20100262117A1 (en) | 2007-11-02 | 2010-10-14 | University Of Virginia Patent Foundation | Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing |
US20100292634A1 (en) * | 2006-06-19 | 2010-11-18 | Dose Safety | System, method and article for controlling the dispensing of insulin |
US7850641B2 (en) | 2001-09-07 | 2010-12-14 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US20110021898A1 (en) | 2009-07-23 | 2011-01-27 | Abbott Diabetes Care Inc. | Real time management of data relating to physiological control of glucose levels |
US20110054391A1 (en) | 2006-07-28 | 2011-03-03 | Ward W Kenneth | Analyte sensing and response system |
CN102077108A (en) | 2008-04-28 | 2011-05-25 | 康奈尔大学 | Tool for accurate quantification in molecular mri |
US20110208155A1 (en) | 2010-02-19 | 2011-08-25 | Medtronic Minimed, Inc. | Closed-loop glucose control startup |
US20110208156A1 (en) | 2010-02-11 | 2011-08-25 | The Regents Of The University Of California | Systems, devices and methods to deliver biological factors or drugs to a subject |
US20120065894A1 (en) | 2009-02-04 | 2012-03-15 | Sanofi-Aventis Deutschland Gmbh | Medical system and method for providing glycemic control based on glycemic response information |
US20120078067A1 (en) | 2009-05-29 | 2012-03-29 | University Of Virginia Patent Foundation | System Coordinator and Modular Architecture for Open-Loop and Closed-Loop Control of Diabetes |
WO2012058694A2 (en) | 2010-10-31 | 2012-05-03 | Trustees Of Boston University | Blood glucose control system |
US8185412B1 (en) | 2008-03-28 | 2012-05-22 | Mahesh Harpale | Method and apparatus for chronic care treatment control with custom named-type factors and user estimation error correction |
JP2012516735A (en) | 2009-02-04 | 2012-07-26 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Medical system and method for providing information for blood glucose control |
WO2012108938A1 (en) | 2011-02-11 | 2012-08-16 | Abbott Diabetes Care Inc. | Software applications residing on handheld analyte determining devices |
JP2012519018A (en) | 2009-02-26 | 2012-08-23 | モール・リサーチ・アプリケーションズ・リミテッド | Method and system for automatically monitoring diabetes related therapy |
CN102667787A (en) | 2009-09-30 | 2012-09-12 | 莫尔研究应用有限公司 | Monitoring device for managing insulin infusion |
US20120245556A1 (en) | 2009-09-01 | 2012-09-27 | University Of Virginia Patent Foundation | System, Method and Computer Program Product For Adjustment of Insulin Delivery in Diabetes Using Nominal Open-Loop Profiles |
US20120265126A1 (en) * | 2008-08-20 | 2012-10-18 | Asante Solutions, Inc. | Infusion Pump Systems and Methods |
US20120265722A1 (en) | 2007-05-24 | 2012-10-18 | Michael Blomquist | Expert system for insulin pump therapy |
US20120277723A1 (en) | 2009-11-04 | 2012-11-01 | Aimedics Pty Ltd | System and method for the integration of fused-data hypoglycaemia alarms into closed-loop glycaemic control systems |
US20120283694A1 (en) | 2009-09-18 | 2012-11-08 | Mendingo Ltd. | Devices, systems and methods for quantifying bolus doses according to user parameters |
CN102802522A (en) | 2010-02-25 | 2012-11-28 | 生命扫描苏格兰有限公司 | Analyte testing method and system with safety warnings for insulin dosing |
CN102812121A (en) | 2010-01-25 | 2012-12-05 | 文特里亚生物科学公司 | Methods & compositions for improving protein production |
US8348842B1 (en) | 2004-05-14 | 2013-01-08 | Flint Hills Scientific, L.L.C. | Method and system for implantable glucose monitoring and control of a glycemic state of a subject |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
CN102946923A (en) | 2010-06-22 | 2013-02-27 | 美敦力迷你迈德公司 | Method and/or system for closed-loop control of glucose to a treatment range |
US8457901B2 (en) | 2008-04-04 | 2013-06-04 | Hygieia, Inc. | System for optimizing a patient's insulin dosage regimen |
US8454510B2 (en) | 2007-06-20 | 2013-06-04 | Medingo Ltd. | Method and device for assessing carbohydrate-to-insulin ratio |
US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
US20130190583A1 (en) | 2012-01-19 | 2013-07-25 | Medtronic Minimed, Inc. | Method and/or system for assessing a patient's glycemic response |
US8562587B2 (en) | 2009-02-25 | 2013-10-22 | University Of Virginia Patent Foundation | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
US8622988B2 (en) | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
US8679016B2 (en) | 2006-12-29 | 2014-03-25 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US8690820B2 (en) | 2009-10-06 | 2014-04-08 | Illinois Institute Of Technology | Automatic insulin pumps using recursive multivariable models and adaptive control algorithms |
WO2014110541A1 (en) | 2013-01-14 | 2014-07-17 | The Regents Of University Of California | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type i diabetes applications |
US8840582B2 (en) | 2008-01-09 | 2014-09-23 | Tandem Diabetes Care, Inc. | Infusion pump with activity monitoring |
US20150018633A1 (en) | 2011-06-23 | 2015-01-15 | University Of Virginia Patent Foundation | Unified Platform for Monitoring and Control of Blood Glucose Levels in Diabetic Patients |
WO2015021041A2 (en) | 2013-08-05 | 2015-02-12 | Hygieia, Inc. | Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus |
CN104667368A (en) | 2015-03-06 | 2015-06-03 | 上海交通大学 | Implementation method for controlling to separate dynamic control of insulin pump from computing |
CN104667379A (en) | 2015-03-06 | 2015-06-03 | 上海交通大学 | Insulin pump with dynamic closed-loop control |
US20150217052A1 (en) | 2014-02-06 | 2015-08-06 | Medtronic Minimed, Inc | Automatic closed-loop control adjustments and infusion systems incorporating same |
US20150217053A1 (en) | 2014-01-31 | 2015-08-06 | Aseko, Inc. | Insulin Management |
US9283323B2 (en) | 2011-08-12 | 2016-03-15 | Gene Onyx Limited | Insulin pump |
US9351670B2 (en) | 2012-12-31 | 2016-05-31 | Abbott Diabetes Care Inc. | Glycemic risk determination based on variability of glucose levels |
US9398869B2 (en) | 2010-03-26 | 2016-07-26 | University Of Virginia Patent Foundation | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes |
US20160224756A1 (en) | 2013-09-20 | 2016-08-04 | Sanofi-Aventis Deutschland Gmbh | Data management unit for supporting health control |
US9445757B2 (en) | 2010-12-29 | 2016-09-20 | Medtronic Minimed, Inc. | Glycemic health metric determination and application |
US9486578B2 (en) | 2012-12-07 | 2016-11-08 | Animas Corporation | Method and system for tuning a closed-loop controller for an artificial pancreas |
US20160331898A1 (en) | 2014-01-31 | 2016-11-17 | Trustees Of Boston University | Glucose level control system with offline control based on preceding periods of online control |
US20170203038A1 (en) | 2016-01-14 | 2017-07-20 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9901677B2 (en) | 2012-10-16 | 2018-02-27 | Bigfoot Biomedical, Inc. | Infusion pump system and methods |
US9907909B2 (en) | 2012-12-20 | 2018-03-06 | Animas Corporation | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
US9999728B2 (en) | 2012-08-30 | 2018-06-19 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
US20180185587A1 (en) | 2004-02-26 | 2018-07-05 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US20180200440A1 (en) | 2017-01-13 | 2018-07-19 | Bigfoot Biomedical, Inc. | Insulin delivery methodes, systems and devices |
US10188793B2 (en) | 2014-06-10 | 2019-01-29 | Bigfoot Biomedical, Inc. | Insulin on board calculation, schedule and delivery |
US20190214124A1 (en) | 2016-07-15 | 2019-07-11 | Universität Bern | Estimation of insulin based on reinforcement learning |
US10463786B2 (en) | 2013-03-15 | 2019-11-05 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
US20190336684A1 (en) | 2018-05-04 | 2019-11-07 | Insulet Corporation | Safety constraints for a control algorithm based drug delivery system |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
US10653834B2 (en) | 2012-06-07 | 2020-05-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
US20200254240A1 (en) | 2016-05-15 | 2020-08-13 | Biolinq, Inc. | Devices and Methods For The Incorporation Of A Microneedle Array Analyte-Selective Sensor Into An Infusion Set, Patch Pump, Or Automated Therapeutic Delivery System |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK85633C (en) | 1953-09-04 | 1958-06-02 | Gestetner Ltd | Duplicating machine. |
CN102346961A (en) * | 2010-07-29 | 2012-02-08 | 鸿富锦精密工业(深圳)有限公司 | Electronic equipment |
-
2015
- 2015-01-26 CN CN202011391971.5A patent/CN112515665B/en active Active
- 2015-01-26 EP EP22167586.1A patent/EP4091541A1/en active Pending
- 2015-01-26 EP EP15744078.5A patent/EP3089667B1/en active Active
- 2015-01-26 CN CN201580017176.0A patent/CN106456064B/en active Active
- 2015-01-26 JP JP2016548643A patent/JP6243546B2/en active Active
- 2015-01-26 WO PCT/US2015/012861 patent/WO2015116524A1/en active Application Filing
- 2015-01-26 AU AU2015211258A patent/AU2015211258A1/en not_active Abandoned
- 2015-01-26 CA CA2938078A patent/CA2938078C/en active Active
- 2015-01-26 DK DK15744078.5T patent/DK3089667T3/en active
-
2016
- 2016-07-25 IL IL246934A patent/IL246934B/en active IP Right Grant
- 2016-07-27 MX MX2016009787A patent/MX373076B/en active IP Right Grant
- 2016-07-27 MX MX2020004660A patent/MX2020004660A/en unknown
- 2016-07-28 US US15/221,871 patent/US10543313B2/en not_active Ceased
-
2017
- 2017-10-30 AU AU2017251868A patent/AU2017251868B2/en active Active
-
2021
- 2021-05-06 US US17/313,401 patent/USRE50075E1/en active Active
Patent Citations (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4280494A (en) | 1979-06-26 | 1981-07-28 | Cosgrove Robert J Jun | System for automatic feedback-controlled administration of drugs |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
JPH03500129A (en) | 1987-08-28 | 1991-01-17 | リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ | Metabolic sensors for drug delivery systems |
US7347836B2 (en) | 1992-09-09 | 2008-03-25 | Smiths Medical, Inc. | Drug pump systems and methods |
US5665065A (en) | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US20030181852A1 (en) | 1998-08-18 | 2003-09-25 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
CA2365316A1 (en) | 1999-04-15 | 2000-10-26 | William G. O'brien | Portable remote patient telemonitoring system |
US20040147872A1 (en) | 1999-04-30 | 2004-07-29 | Medtronic, Inc. | Closed loop medicament pump |
JP2001204817A (en) | 1999-11-18 | 2001-07-31 | Roche Diagnostics Gmbh | System for extrapolation of glucose concentration |
JP2004502474A (en) | 2000-02-10 | 2004-01-29 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | Apparatus and method for administering a proper amount of a hormone that regulates blood glucose in a patient |
US6572542B1 (en) | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
US20040034295A1 (en) | 2000-09-26 | 2004-02-19 | Marcos Salganicoff | Method and apparatus for real-time estimation and control of physiological parameters |
US20040028707A1 (en) | 2001-06-29 | 2004-02-12 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
JP2003079723A (en) | 2001-07-31 | 2003-03-18 | F Hoffmann-La Roche Ag | Diabetes management device |
US7850641B2 (en) | 2001-09-07 | 2010-12-14 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US7491187B2 (en) | 2002-03-22 | 2009-02-17 | K.U. Leuven Research & Development | Automatic infusion system based on an adaptive patient model |
WO2004006982A2 (en) | 2002-07-15 | 2004-01-22 | Insulet Corporation | Self-contained, automatic transcutaneous physiologic sensing system |
EP1575656A1 (en) | 2002-10-11 | 2005-09-21 | Becton, Dickinson and Company | Insulin delivery system with sensor |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7678763B2 (en) | 2002-12-27 | 2010-03-16 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US7678762B2 (en) | 2002-12-27 | 2010-03-16 | Diobex, Inc. | Methods for reducing the risk of hypoglycemia |
US7683027B2 (en) | 2002-12-27 | 2010-03-23 | Diobex, Inc. | Methods relating to hypoglycemic unawareness |
WO2004084820A2 (en) | 2003-03-19 | 2004-10-07 | Harry Hebblewhite | Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
US20040253736A1 (en) | 2003-06-06 | 2004-12-16 | Phil Stout | Analytical device with prediction module and related methods |
US20180185587A1 (en) | 2004-02-26 | 2018-07-05 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US20070282299A1 (en) | 2004-03-08 | 2007-12-06 | Robert Hellwig | Method and Device for Calculating a Bolus Amount |
JP2007529241A (en) | 2004-03-08 | 2007-10-25 | ディセトロニック・ライセンシング・アクチェンゲゼルシャフト | Method and apparatus for calculating bolus amount |
US20050272640A1 (en) | 2004-05-13 | 2005-12-08 | Doyle Francis J Iii | Method and apparatus for glucose control and insulin dosing for diabetics |
US7651845B2 (en) | 2004-05-13 | 2010-01-26 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
US8348842B1 (en) | 2004-05-14 | 2013-01-08 | Flint Hills Scientific, L.L.C. | Method and system for implantable glucose monitoring and control of a glycemic state of a subject |
US20110106049A1 (en) | 2005-05-13 | 2011-05-05 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
WO2006124716A2 (en) | 2005-05-13 | 2006-11-23 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
US7806854B2 (en) | 2005-05-13 | 2010-10-05 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
US20080208113A1 (en) * | 2005-05-13 | 2008-08-28 | Trustees Of Boston University | Fully Automated Control System for Type I Diabetes |
US8273052B2 (en) | 2005-05-13 | 2012-09-25 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
US20060272652A1 (en) * | 2005-06-03 | 2006-12-07 | Medtronic Minimed, Inc. | Virtual patient software system for educating and treating individuals with diabetes |
US20060276771A1 (en) | 2005-06-06 | 2006-12-07 | Galley Paul J | System and method providing for user intervention in a diabetes control arrangement |
US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
CN1973768A (en) | 2005-11-28 | 2007-06-06 | 中国科学院电子学研究所 | Non-invasive blood sugar instrument for closed-loop insulin injection |
EP1860583A2 (en) | 2006-05-24 | 2007-11-28 | Sysmex Corporation | Simulation system of function of biological organ |
JP2007312923A (en) | 2006-05-24 | 2007-12-06 | Sysmex Corp | System for simulating function of biological organ and program for the same |
US20140031786A1 (en) | 2006-06-19 | 2014-01-30 | Dose Safety | System, method and article for controlling the dispensing of insulin |
US20100292634A1 (en) * | 2006-06-19 | 2010-11-18 | Dose Safety | System, method and article for controlling the dispensing of insulin |
US20110054391A1 (en) | 2006-07-28 | 2011-03-03 | Ward W Kenneth | Analyte sensing and response system |
WO2008057384A2 (en) | 2006-11-02 | 2008-05-15 | The University Of North Carolina At Chapel Hill | Methods and systems for determining an intravenous insulin infusion rate |
US20100137788A1 (en) | 2006-11-02 | 2010-06-03 | Braithwaite Susan S | Methods and systems for determining an intravenous insulin infusion rate to correct hyperglycemia of a patient, to maintain euglycemia of a patient, and to prevent hypoglycemia of a patient |
US20080154187A1 (en) | 2006-12-21 | 2008-06-26 | Lifescan, Inc. | Malfunction detection in infusion pumps |
US8679016B2 (en) | 2006-12-29 | 2014-03-25 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
WO2008094249A1 (en) | 2007-01-31 | 2008-08-07 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
US20080183060A1 (en) | 2007-01-31 | 2008-07-31 | Steil Garry M | Model predictive method and system for controlling and supervising insulin infusion |
WO2008114254A1 (en) | 2007-03-19 | 2008-09-25 | Medingo Ltd. | User interface for selecting bolus doses in a drug delivery device |
US20100082167A1 (en) | 2007-04-19 | 2010-04-01 | Disetronic Licensing Ag | Method for setting a basal rate profile for an insulin pump |
US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
US20100145262A1 (en) | 2007-05-03 | 2010-06-10 | Novo Nordisk A/S | Safety system for insulin delivery advisory algorithms |
US10357607B2 (en) | 2007-05-24 | 2019-07-23 | Tandem Diabetes Care, Inc. | Correction factor testing using frequent blood glucose input |
US20120265722A1 (en) | 2007-05-24 | 2012-10-18 | Michael Blomquist | Expert system for insulin pump therapy |
US8454510B2 (en) | 2007-06-20 | 2013-06-04 | Medingo Ltd. | Method and device for assessing carbohydrate-to-insulin ratio |
WO2008157780A1 (en) | 2007-06-21 | 2008-12-24 | University Of Virginia Patent Foundation | Lqg artificial pancreas control system and related method |
US20080319384A1 (en) | 2007-06-25 | 2008-12-25 | Medingo, Ltd. | Tailored Basal Insulin Delivery System and Method |
WO2009001349A1 (en) | 2007-06-25 | 2008-12-31 | Medingo Ltd. | Tailored basal insulin delivery system |
US20090006061A1 (en) | 2007-06-27 | 2009-01-01 | Roche Diagnostics Operations, Inc. | System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof |
CN101821741A (en) | 2007-06-27 | 2010-09-01 | 霍夫曼-拉罗奇有限公司 | Medical diagnosis, therapy, and prognosis system for invoked events and method thereof |
CN101795623A (en) | 2007-09-07 | 2010-08-04 | 泰尔茂株式会社 | Blood sugar measuring device |
US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US20100262117A1 (en) | 2007-11-02 | 2010-10-14 | University Of Virginia Patent Foundation | Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing |
US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US20090177154A1 (en) | 2008-01-08 | 2009-07-09 | Michael Blomquist | Insulin pump with convenience features |
US8840582B2 (en) | 2008-01-09 | 2014-09-23 | Tandem Diabetes Care, Inc. | Infusion pump with activity monitoring |
US8185412B1 (en) | 2008-03-28 | 2012-05-22 | Mahesh Harpale | Method and apparatus for chronic care treatment control with custom named-type factors and user estimation error correction |
US8457901B2 (en) | 2008-04-04 | 2013-06-04 | Hygieia, Inc. | System for optimizing a patient's insulin dosage regimen |
CN102077108A (en) | 2008-04-28 | 2011-05-25 | 康奈尔大学 | Tool for accurate quantification in molecular mri |
CN201186082Y (en) | 2008-05-05 | 2009-01-28 | 王安宇 | Intelligent input mechanism for insulins and glucose |
US20120265126A1 (en) * | 2008-08-20 | 2012-10-18 | Asante Solutions, Inc. | Infusion Pump Systems and Methods |
US8622988B2 (en) | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
US20100057057A1 (en) | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Closed Loop Control And Signal Attenuation Detection |
US20100125241A1 (en) | 2008-11-17 | 2010-05-20 | Disetronic Licensing, Ag | Prandial Blood Glucose Excursion Optimization Method Via Computation of Time-Varying Optimal Insulin Profiles and System Thereof |
JP2012516735A (en) | 2009-02-04 | 2012-07-26 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Medical system and method for providing information for blood glucose control |
US20120065894A1 (en) | 2009-02-04 | 2012-03-15 | Sanofi-Aventis Deutschland Gmbh | Medical system and method for providing glycemic control based on glycemic response information |
US9750438B2 (en) | 2009-02-25 | 2017-09-05 | University Of Virginia Patent Foundation | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
US8562587B2 (en) | 2009-02-25 | 2013-10-22 | University Of Virginia Patent Foundation | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
JP2012519018A (en) | 2009-02-26 | 2012-08-23 | モール・リサーチ・アプリケーションズ・リミテッド | Method and system for automatically monitoring diabetes related therapy |
US20100256466A1 (en) | 2009-04-02 | 2010-10-07 | Avraham Shekalim | Metabolite Management System |
US20120078067A1 (en) | 2009-05-29 | 2012-03-29 | University Of Virginia Patent Foundation | System Coordinator and Modular Architecture for Open-Loop and Closed-Loop Control of Diabetes |
US20110021898A1 (en) | 2009-07-23 | 2011-01-27 | Abbott Diabetes Care Inc. | Real time management of data relating to physiological control of glucose levels |
US8478557B2 (en) | 2009-07-31 | 2013-07-02 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
US20120245556A1 (en) | 2009-09-01 | 2012-09-27 | University Of Virginia Patent Foundation | System, Method and Computer Program Product For Adjustment of Insulin Delivery in Diabetes Using Nominal Open-Loop Profiles |
US20120283694A1 (en) | 2009-09-18 | 2012-11-08 | Mendingo Ltd. | Devices, systems and methods for quantifying bolus doses according to user parameters |
CN102667787A (en) | 2009-09-30 | 2012-09-12 | 莫尔研究应用有限公司 | Monitoring device for managing insulin infusion |
US20120246106A1 (en) | 2009-09-30 | 2012-09-27 | Mor Research Applications Ltd. | Monitoring device for management of insulin delivery |
US8690820B2 (en) | 2009-10-06 | 2014-04-08 | Illinois Institute Of Technology | Automatic insulin pumps using recursive multivariable models and adaptive control algorithms |
US20120277723A1 (en) | 2009-11-04 | 2012-11-01 | Aimedics Pty Ltd | System and method for the integration of fused-data hypoglycaemia alarms into closed-loop glycaemic control systems |
CN102812121A (en) | 2010-01-25 | 2012-12-05 | 文特里亚生物科学公司 | Methods & compositions for improving protein production |
US20110208156A1 (en) | 2010-02-11 | 2011-08-25 | The Regents Of The University Of California | Systems, devices and methods to deliver biological factors or drugs to a subject |
US20110208155A1 (en) | 2010-02-19 | 2011-08-25 | Medtronic Minimed, Inc. | Closed-loop glucose control startup |
CN102802522A (en) | 2010-02-25 | 2012-11-28 | 生命扫描苏格兰有限公司 | Analyte testing method and system with safety warnings for insulin dosing |
US9398869B2 (en) | 2010-03-26 | 2016-07-26 | University Of Virginia Patent Foundation | Method, system, and computer program product for improving the accuracy of glucose sensors using insulin delivery observation in diabetes |
CN102946923A (en) | 2010-06-22 | 2013-02-27 | 美敦力迷你迈德公司 | Method and/or system for closed-loop control of glucose to a treatment range |
US10188795B2 (en) | 2010-10-31 | 2019-01-29 | Trustees Of Boston University | Blood glucose control system |
WO2012058694A2 (en) | 2010-10-31 | 2012-05-03 | Trustees Of Boston University | Blood glucose control system |
US9833570B2 (en) | 2010-10-31 | 2017-12-05 | Trustees Of Boston University | Blood glucose control system |
US20170095612A1 (en) | 2010-10-31 | 2017-04-06 | Trustees Of Boston University | Blood glucose control system |
US9445757B2 (en) | 2010-12-29 | 2016-09-20 | Medtronic Minimed, Inc. | Glycemic health metric determination and application |
WO2012108938A1 (en) | 2011-02-11 | 2012-08-16 | Abbott Diabetes Care Inc. | Software applications residing on handheld analyte determining devices |
US20150018633A1 (en) | 2011-06-23 | 2015-01-15 | University Of Virginia Patent Foundation | Unified Platform for Monitoring and Control of Blood Glucose Levels in Diabetic Patients |
US9283323B2 (en) | 2011-08-12 | 2016-03-15 | Gene Onyx Limited | Insulin pump |
US20130190583A1 (en) | 2012-01-19 | 2013-07-25 | Medtronic Minimed, Inc. | Method and/or system for assessing a patient's glycemic response |
US10653834B2 (en) | 2012-06-07 | 2020-05-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
US9999728B2 (en) | 2012-08-30 | 2018-06-19 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
US9901677B2 (en) | 2012-10-16 | 2018-02-27 | Bigfoot Biomedical, Inc. | Infusion pump system and methods |
US9486578B2 (en) | 2012-12-07 | 2016-11-08 | Animas Corporation | Method and system for tuning a closed-loop controller for an artificial pancreas |
US9907909B2 (en) | 2012-12-20 | 2018-03-06 | Animas Corporation | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
US9351670B2 (en) | 2012-12-31 | 2016-05-31 | Abbott Diabetes Care Inc. | Glycemic risk determination based on variability of glucose levels |
WO2014110541A1 (en) | 2013-01-14 | 2014-07-17 | The Regents Of University Of California | Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type i diabetes applications |
US10463786B2 (en) | 2013-03-15 | 2019-11-05 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
WO2015021041A2 (en) | 2013-08-05 | 2015-02-12 | Hygieia, Inc. | Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus |
US20160224756A1 (en) | 2013-09-20 | 2016-08-04 | Sanofi-Aventis Deutschland Gmbh | Data management unit for supporting health control |
US20150217053A1 (en) | 2014-01-31 | 2015-08-06 | Aseko, Inc. | Insulin Management |
US20160331898A1 (en) | 2014-01-31 | 2016-11-17 | Trustees Of Boston University | Glucose level control system with offline control based on preceding periods of online control |
US10543313B2 (en) | 2014-01-31 | 2020-01-28 | Trustees Of Boston University | Glucose level control system with offline control based on preceding periods of online control |
US20150217052A1 (en) | 2014-02-06 | 2015-08-06 | Medtronic Minimed, Inc | Automatic closed-loop control adjustments and infusion systems incorporating same |
US10188793B2 (en) | 2014-06-10 | 2019-01-29 | Bigfoot Biomedical, Inc. | Insulin on board calculation, schedule and delivery |
CN104667368A (en) | 2015-03-06 | 2015-06-03 | 上海交通大学 | Implementation method for controlling to separate dynamic control of insulin pump from computing |
CN104667379A (en) | 2015-03-06 | 2015-06-03 | 上海交通大学 | Insulin pump with dynamic closed-loop control |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
EP3453414A1 (en) | 2016-01-14 | 2019-03-13 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
US20190247578A1 (en) | 2016-01-14 | 2019-08-15 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
US20170203038A1 (en) | 2016-01-14 | 2017-07-20 | Bigfoot Biomedical, Inc. | Adjusting insulin delivery rates |
US20200254240A1 (en) | 2016-05-15 | 2020-08-13 | Biolinq, Inc. | Devices and Methods For The Incorporation Of A Microneedle Array Analyte-Selective Sensor Into An Infusion Set, Patch Pump, Or Automated Therapeutic Delivery System |
US20190214124A1 (en) | 2016-07-15 | 2019-07-11 | Universität Bern | Estimation of insulin based on reinforcement learning |
US20180200440A1 (en) | 2017-01-13 | 2018-07-19 | Bigfoot Biomedical, Inc. | Insulin delivery methodes, systems and devices |
US20190336684A1 (en) | 2018-05-04 | 2019-11-07 | Insulet Corporation | Safety constraints for a control algorithm based drug delivery system |
Non-Patent Citations (34)
Title |
---|
Albisser et al., May 1974, An Artificial Endocrine Pancreas, Diabetes, 23(5):389-396. |
Bellazzi et al., 1995, Adaptive Controllers for Intelligent Monitoring, Artif. Intell. Med., 7:515-540. |
Bellomo et al., May 1982, Optimal Feedback Glycaemia Regulation in Diabetics, Med. & Biol. Eng. & Comp. 20:329-335. |
Berian et al., 2019, A wearable closed-loop insulin delivery systme based on low-power SoCs, Electronics, 8:612. |
Botz, May 1976, An Improved Control Algorithm for an Artificial β-Cell, IEEE Trans. Biomed. Eng., BME-23(3):252-255. |
Brunetti et al., 1993, A Simulation Study on a Self-Tuning Portable Controller of Blood Glucose, Int. J. Artif. Org., 16(1):51-57. |
Candas et al., Feb. 1994, An Adaptive Plasma Glucose Controller Based on a Nonlinear Insulin/Glucose Model, IEEE Trans. Biomed. Eng. 41(2):116-124. |
Clemens, 1979, Feedback Control Dynamics for Glucose Controlled Insulin Infusion Systems, Med. Prog. Technol. 6:91-98. |
El-Khatib et al., Apr. 14, 2010, A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes, Science.Trans. Med., 2(27):1-12. |
El-Khatib et al., Jul. 2009, A Feasibility Study of Bihormonal Closed-Loop Blood-Glucose Control Using Dual Subcutaneous Infusion of Insulin and Glucagon in Ambulatory Diabetic Swine, Journal of Diabetes Science and Technology, 3(4):789-803. |
El-Khatib, et al., Mar. 2007, Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Dual Subcutaneous Insulin nd Glucagon Infusion in Diabetic Swine, Journal of Diabetes Science and Technology, 1(2):181-192. |
El-Khatib, et al., May 2014, Autonomous and Continuous Adaptation of a Bihormonal Bionic Pancreas in Adults and Adolescents Nilh Type 1 Diabetes, Journal of Clinical Endocrin. Melab., 99(5):1701-1711. |
Femat et al., Aug. 22-27, 1999, Blood Glucose Regulation: An Output Feedback Approach, Proc. IEEE Int. Conf. Control App. pp. 1290-1293. |
Fischer et al., Aug. 1987, Does Physiological Blood Glucose Control Require an Adaptive Control Strategy?, IEEE Trans. Biomed. Eng., BME-34:575-582. |
Fletcher et al., 2001, Feasibility of an Implanted, Closed-Loop, Blood-Glucose Control Device, Immunology 230, Stanford University, Spring 01, 31 pp. |
Furler et al., Nov.-Dec. 1985, Blood Glucose Control by Intermittent Loop Closure in the Basal Mode: Computer Simulation Studies with a Diabetic Model, Diabetes Care, 8(6):553-561. |
Kan et al., 2000, Novel Control System for Blood Glucose Using a Model Predictive Method, ASAIO Journal, 4:657-662. |
Lal et al., Jul. 5, 2019, Realizing a closed-loop (artifical pancreas) system for the treatment of type 1 diabetes, Endocrine reviews, 40(6):1521-1546. |
Lauritzen et al., May 1983 Pharmacokinetics of Continuous Subcutaneous Insulin Infusion, Diabetologia, 24(5):326-329. |
Marliss et al., Jul. 1977, Normalization of Glycemia in Diabetics During Meals with Insulin and Glucagon Delivery by the Artificial Pancreas, Diabetes, 26:663-672. |
Medtronic, 2020, Minimed™ 670G Insulin Pump System, product brochure, https://www.medtronicdiabetes.com/products/minimed-670g-insulin-pump-system, 7 pp. |
Pagurek et al., 1972, Adaptive Control of the Human Glucose Regulatory System, Med. Biol. Eng., 10:752-761. |
Panteleon et al., Jul. 2006, Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system, Diabetes, 55:1995-2000. |
Parker et al., 1996, Model Predictive Control for Infusion Pump Insulin Delivery, Proceedings of the 18th Annual International Conference of the IEEE, 6:1822-1823. |
Parker et al., Feb. 1999, A Model-Based Algorithm for Blood Glucose Control in Type I Diabetic Patients, IEEE Trans. Biomed. Eng. 46(2):148-157. |
Parker et al., Jan.-Feb. 2001, The Intravenous Route to Blood Glucose Control, IEEE Eng. Med. & Biol., pp. 65-73. |
Parrish et al., Jun. 1997, Control of an Artificial Human Pancreas Using the SDRE Method, Proc. American Control Conf., 2:1059-1060. |
Russell et al., Nov. 2010, Efficacy Determinants of Subcutaneous Microdose Glucagon during Closed-Loop Control, Journal of Diabetes Science and Technology, 4(6):1288-1304. |
Russell, et al., Jun. 15, 2014, Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes, The New England Journal of Medicine, 371(4):313-325. |
Russell, et al., Nov. 2012, Blood Glucose Control in Type 1 Diabetes With a Bihormonal Bionic Endocrine Pancreas, Diabetes Care, 35:2148-2155. |
Sivaramakrishnan et al., 2017, Optimal model based control for blood glucose insulin system using continuous glucose monitoring, J. Pharm. Sci & Res., 9(4):465-469. |
Steil et al., 2006, Metabolic modelling and the closed-loop insulin delivery problem, Diabetes Research and Clinical Practice, 74:S183-S186. |
Steil et al., Dec. 2006, Feasibility of automating insulin delivery for the treatment of type 1 diabetes, Diabetes, 55:3344-3350. |
Trajanoski et al., Sep. 1998, Neural Predictive Controller for Insulin Delivery Using the Subcutaneous Route, Biomedical Engineering, 45(9):1122-1134. |
Also Published As
Publication number | Publication date |
---|---|
MX373076B (en) | 2025-03-05 |
JP6243546B2 (en) | 2017-12-06 |
DK3089667T3 (en) | 2022-05-09 |
EP3089667A1 (en) | 2016-11-09 |
MX2016009787A (en) | 2017-02-22 |
CN112515665B (en) | 2024-03-29 |
AU2017251868A1 (en) | 2017-11-16 |
CN106456064A (en) | 2017-02-22 |
IL246934A0 (en) | 2016-09-29 |
EP3089667A4 (en) | 2017-09-13 |
WO2015116524A1 (en) | 2015-08-06 |
AU2017251868B2 (en) | 2019-07-11 |
CN106456064B (en) | 2020-11-27 |
US20160331898A1 (en) | 2016-11-17 |
CA2938078A1 (en) | 2015-08-06 |
EP3089667B1 (en) | 2022-04-13 |
AU2015211258A1 (en) | 2016-08-11 |
CA2938078C (en) | 2019-06-11 |
MX2020004660A (en) | 2020-07-24 |
JP2017511911A (en) | 2017-04-27 |
EP4091541A1 (en) | 2022-11-23 |
IL246934B (en) | 2021-05-31 |
US10543313B2 (en) | 2020-01-28 |
CN112515665A (en) | 2021-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE50075E1 (en) | Glucose level control system with offline control based on preceding periods of online control | |
US11040141B2 (en) | Blood glucose control system with carbohydrate therapy indication | |
USRE50080E1 (en) | Blood glucose control system | |
US11957876B2 (en) | Glucose control system with automated backup therapy protocol generation | |
EP4042436A1 (en) | Blood glucose control system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: TRUSTEES OF BOSTON UNIVERSITY, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAMIANO, EDWARD R.;EL-KHATIB, FIRAS H.;REEL/FRAME:056913/0152 Effective date: 20151207 |